Categories
Change Password!
Reset Password!
This study aimed to determine influence of probiotic supplementation during pregnancy on risk of gestational diabetes mellitus (GDM) and also other neonatal and maternal outcomes.
In high-risk pregnant females, supplementing
probiotics from the 1st half of 2nd trimester (14 weeks
of pregnancy) up to 24 weeks of pregnancy does not decrease the risk of
gestational diabetes mellitus, or improve other maternal and neonatal outcomes.
This study aimed to determine influence of
probiotic supplementation during pregnancy on risk of gestational diabetes
mellitus (GDM) and also other neonatal and maternal outcomes.
In this randomized, double-blind, placebo-controlled, single-center clinical trial, the recruited pregnant females (n=542, mean age 32.03 years, body mass index [BMI] 30.20 kg/m2) were randomly assigned to either probiotic supplement group (n = 271) or placebo (n = 271) group from the 1st half of the second trimester up to 24 weeks when the pregnant females were routinely assessed regarding GDM.
Each probiotic capsule (500 mg) was a mixture of Bifidobacterium bifidum, Bifidobacterium longum, and Lactobacillus acidophilus. During 24-28
weeks of pregnancy, evaluation of mothers with respect to GDM presence was done
with the aid of 75 g oral glucose tolerance test (OGTT). Determination of
fasting blood glucose (FBG) was also done within OGTT processes.
In terms of FBG, OGTT-1h, OGTT-2h, and incidence of GDM, no profound differences were witnessed between the two groups, as shown in Table 1:
Regarding other studied parameters, no considerable differences
was reported.
Probiotics, administered throughout the
pregnancy from the 14th week is not beneficial for minimizing GDM
risk. Also, daily consumption of probiotic supplements by pregnant females does
not modify any of the neonatal and mother outcomes.
Biomedicine & Pharmacotherapy
The effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: A parallel double-blind, randomized, placebo-controlled clinical trial
Ali Shahriari et al.
Comments (0)